Neothetics, Inc. (NASDAQ: NEOT) shares gained 3.2% to $1.45, as it announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. Share volume totaled 43,000, compared to an all-day average of 154,000
